Skip to content
Screener

Interest Income at other companies

Incyte logo
IncyteINCY
$38.12M+51.6%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$4.61M+12.6%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$8.74M+11.5%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$1.78M+240%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$4.24M+47.6%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$1.76M-12.7%

Segments

By segment

See full
Single Reportable$6.43M-13.2%

Other financials

Income statement

See full
Revenue$213.5M+3,749%
Operating income$158.8M+478%
Net income$162.8M+568%
EPS (diluted)$2.29+516%

Balance sheet

See full
Cash & equivalents$420.1M+149%
Total debt$9.2M-18.3%
Total equity$841.5M+26.0%
Total assets$885.5M+23.3%

Cash flow

See full
Operating cash flow$219.1M
CapEx$168.0K-79.3%
Free cash flow$218.9M

Valuation

See full
Market cap$8.83B+165%
Enterprise value$8.42B+165%
P/E106.5×+42.4×
P/S31.3×+15.4×

Profitability

See full
Operating margin20.7%+9.2pp
Net margin29.4%+4.5pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity11%+2.4pp
Debt / equity0.0×
Current ratio21.7×+4.7×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091123
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
General and administrative12,64810,55125,92522,289
Total operating expenses54,70947,587114,72595,218
Income (loss) from operations158,766(42,041)155,118(61,351)
Interest income6,4297,40612,30514,979
Other (expense) income, net(81)36(28)118
Income (loss) before income tax expense165,114(34,599)167,395(46,254)
Income tax expense2,265172763172
Net income (loss)$162,849$(34,771)$166,632$(46,426)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Protagonist Therapeutics's interest income?
Protagonist Therapeutics (PTGX) reported interest income of $6.43M in Q2 2026.
How has Protagonist Therapeutics's interest income changed year-over-year?
Protagonist Therapeutics's interest income decreased by 13.2% year-over-year, from $7.41M to $6.43M.
What is the long-term trend for Protagonist Therapeutics's interest income?
Over 4 years (2021 to 2025), Protagonist Therapeutics's interest income has grown at a 183.9% compound annual growth rate (CAGR), from $443K to $28.79M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Protagonist Therapeutics's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude